Clinical trial · Observational
Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer
Evaluation of the Relationship Between Drug Therapy, Food Consumption, Body Composition and Plasma Micronutients Levels With the Expression of Genes Related to Metabolism, Aging and Immunity in Women With Breast Cancer.
NCT04389424CI-TRIAL-00045118NUTRIBREASTunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Endocrine Therapy | — | UNRESOLVED | — |
| Endocrine Therapy Adverse Reaction | — | UNRESOLVED | — |
| Nutrition Disorders | — | UNRESOLVED | — |
| Obesity | — | UNRESOLVED | — |
| Vitamin D Deficiency | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastrozole | Drug | Anastrozole | ALIAS |
| Basal | Diagnostic Test | — | UNRESOLVED |
| Exemestane | Drug | Exemestane | ALIAS |
| Recurrence | Diagnostic Test | — | UNRESOLVED |
| Tamoxifen | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (5)
- label
- Anastrozole
- description
- Breast cancer women with anastrozole treatment
- interventionNames
- Drug: Anastrozole
- label
- Tamoxifen
- description
- Breast cancer women with tamoxifen treatment
- interventionNames
- Drug: Tamoxifen
- label
- Exemestane
- description
- Breast cancer women with exemestane treatment
- interventionNames
- Drug: Exemestane
- label
- Basal
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 98 Years
Show eligibility criteria text
Inclusion Criteria: * Breast cancer women under endocrine therapy or recurrence of disease after endocrine therapy * Signed consent Exclusion Criteria: * Mental retardation
References
Publications (0)
Data not yet available
No reference posted for this study.